TY - JOUR
T1 - Multi-omics of the gut microbial ecosystem in inflammatory bowel diseases
AU - IBDMDB Investigators
AU - Lloyd-Price, Jason
AU - Arze, Cesar
AU - Ananthakrishnan, Ashwin N.
AU - Schirmer, Melanie
AU - Avila-Pacheco, Julian
AU - Poon, Tiffany W.
AU - Andrews, Elizabeth
AU - Ajami, Nadim J.
AU - Bonham, Kevin S.
AU - Brislawn, Colin J.
AU - Casero, David
AU - Courtney, Holly
AU - Gonzalez, Antonio
AU - Graeber, Thomas G.
AU - Hall, A. Brantley
AU - Lake, Kathleen
AU - Landers, Carol J.
AU - Mallick, Himel
AU - Plichta, Damian R.
AU - Prasad, Mahadev
AU - Rahnavard, Gholamali
AU - Sauk, Jenny
AU - Shungin, Dmitry
AU - Vázquez-Baeza, Yoshiki
AU - White, Richard A.
AU - Bishai, Jason
AU - Bullock, Kevin
AU - Deik, Amy
AU - Dennis, Courtney
AU - Kaplan, Jess L.
AU - Khalili, Hamed
AU - McIver, Lauren J.
AU - Moran, Christopher J.
AU - Nguyen, Long
AU - Pierce, Kerry A.
AU - Schwager, Randall
AU - Sirota-Madi, Alexandra
AU - Stevens, Betsy W.
AU - Tan, William
AU - ten Hoeve, Johanna J.
AU - Weingart, George
AU - Wilson, Robin G.
AU - Yajnik, Vijay
AU - Braun, Jonathan
AU - Denson, Lee A.
AU - Jansson, Janet K.
AU - Knight, Rob
AU - Kugathasan, Subra
AU - McGovern, Dermot P.B.
AU - Stappenbeck, Thaddeus S.
N1 - Funding Information:
Acknowledgements We thank G. Ackermann, E. X. Li, J. Livny, D. McDonald, C. Moran, A. Robbins-Pianka, and S. Sun for their contributions during this project; the Broad Institute of MIT and Harvard Microbial ‘Omics Core, Genomics Platform, and the Harvard T. H. Chan School of Public Health Microbiome Analysis Core for data generation and management; and T. Reimels for editorial assistance. This work was supported by National Institutes of Health grants P01DK046763 (D.P.B.M.), U01DK062413 (D.P.B.M.), U54DK102557 (D.P.B.M.), UL1TR001881 (J.B.), P30DK043351 (R.J.X.), R24DK110499 (C.H.), R01HG005969 (C.H.), U54DE023798 (C.H. and R.J.X.), National Science Foundation grant DBI-1053486 (C.H.), and Army Research Office grant W911NF-11-1-0473 (C.H.). D.S. was supported by the Swedish Research Council International Career Fellowship (4.1-2016-00416). A.B.H. is a Merck Fellow of the Helen Hay Whitney Foundation. A.N.A. was supported by the Crohn’s and Colitis Foundation. D.P.B.M. was supported by the Leona M. and Harry B. Helmsley Charitable Trust. Pacific Northwest National Laboratory is a multi-program laboratory operated by Battelle for the US Department of Energy under contract DE-AC05-76RL01830.
Funding Information:
Protocols and data (both raw and summarized to data type-dependent profiles) are available at the IBDMDB website (https://ibdmdb.org), the HMP DACC web portal (https://www.hmpdacc.org/ihmp/), and Qiita97 (https://qiita.ucsd.edu/). Sequence data are available from SRA BioProject PRJNA398089. Expression data have been deposited in the NCBI Gene Expression Omnibus98 and is accessible through GEO Series accession number GSE111889. Metabolomics data are available at the NIH Common Fund’s Metabolomics Data Repository and Coordinating Center (supported by NIH grant U01-DK097430) website, the Metabolomics Workbench (http://www.metabolomicsworkbench.org), where it has been assigned Project ID PR000639. Mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE99 partner repository with the data set identifiers PXD008675 and 10.6019/PXD008675. Reprints and permissions information is available at www.nature.com/reprints.
Publisher Copyright:
© 2019, The Author(s).
PY - 2019/5/30
Y1 - 2019/5/30
N2 - Inflammatory bowel diseases, which include Crohn’s disease and ulcerative colitis, affect several million individuals worldwide. Crohn’s disease and ulcerative colitis are complex diseases that are heterogeneous at the clinical, immunological, molecular, genetic, and microbial levels. Individual contributing factors have been the focus of extensive research. As part of the Integrative Human Microbiome Project (HMP2 or iHMP), we followed 132 subjects for one year each to generate integrated longitudinal molecular profiles of host and microbial activity during disease (up to 24 time points each; in total 2,965 stool, biopsy, and blood specimens). Here we present the results, which provide a comprehensive view of functional dysbiosis in the gut microbiome during inflammatory bowel disease activity. We demonstrate a characteristic increase in facultative anaerobes at the expense of obligate anaerobes, as well as molecular disruptions in microbial transcription (for example, among clostridia), metabolite pools (acylcarnitines, bile acids, and short-chain fatty acids), and levels of antibodies in host serum. Periods of disease activity were also marked by increases in temporal variability, with characteristic taxonomic, functional, and biochemical shifts. Finally, integrative analysis identified microbial, biochemical, and host factors central to this dysregulation. The study’s infrastructure resources, results, and data, which are available through the Inflammatory Bowel Disease Multi’omics Database (http://ibdmdb.org), provide the most comprehensive description to date of host and microbial activities in inflammatory bowel diseases.
AB - Inflammatory bowel diseases, which include Crohn’s disease and ulcerative colitis, affect several million individuals worldwide. Crohn’s disease and ulcerative colitis are complex diseases that are heterogeneous at the clinical, immunological, molecular, genetic, and microbial levels. Individual contributing factors have been the focus of extensive research. As part of the Integrative Human Microbiome Project (HMP2 or iHMP), we followed 132 subjects for one year each to generate integrated longitudinal molecular profiles of host and microbial activity during disease (up to 24 time points each; in total 2,965 stool, biopsy, and blood specimens). Here we present the results, which provide a comprehensive view of functional dysbiosis in the gut microbiome during inflammatory bowel disease activity. We demonstrate a characteristic increase in facultative anaerobes at the expense of obligate anaerobes, as well as molecular disruptions in microbial transcription (for example, among clostridia), metabolite pools (acylcarnitines, bile acids, and short-chain fatty acids), and levels of antibodies in host serum. Periods of disease activity were also marked by increases in temporal variability, with characteristic taxonomic, functional, and biochemical shifts. Finally, integrative analysis identified microbial, biochemical, and host factors central to this dysregulation. The study’s infrastructure resources, results, and data, which are available through the Inflammatory Bowel Disease Multi’omics Database (http://ibdmdb.org), provide the most comprehensive description to date of host and microbial activities in inflammatory bowel diseases.
UR - http://www.scopus.com/inward/record.url?scp=85066076314&partnerID=8YFLogxK
U2 - 10.1038/s41586-019-1237-9
DO - 10.1038/s41586-019-1237-9
M3 - Article
C2 - 31142855
AN - SCOPUS:85066076314
SN - 0028-0836
VL - 569
SP - 655
EP - 662
JO - Nature
JF - Nature
IS - 7758
ER -